Cleerly Comprehensive Care Management Platform
AI-enabled CCTA solution for personalized, precise and measurable assessment of plaque,
stenosis and ischemia
Request a Demo
Precise AI-driven coronary CTA analysis
Cleerly uses proprietary and FDA-cleared machine learning algorithms to non-invasively measure atherosclerosis (plaque), stenosis, and likelihood of ischemia using coronary computed tomography angiography (CCTA) studies.
Our machine-learning AI generates a 3D model of the patient’s coronary arteries, identifies their lumen and vessel walls, locates and measures stenoses, while quantifying and categorizing plaque.1 Cleerly ISCHEMIA’s algorithm uses measurements based on invasive FFR data to determine the likelihood of vessel-level ischemia.2
These sets of quantitative measurements are presented in a comprehensive report to support providers in efficient diagnosis and personalized patient treatment. Physicians can also review results in depth via our interactive web platform.
Cleerly’s analyses are grounded in science, based on over 10 million images from over 40,000 patients gathered over a 15-year-period in landmark, multi-center clinical trials.3 In a number of clinical studies, Cleerly has shown to be comparable to invasive gold standards, including IVUS4, NIRS5, FFR6, OCT7 and QCA.8
Personalized analysis and treatment
Cleerly’s comprehensive coronary plaque, stenosis and ischemia analyses provides actionable insights for physicians that go beyond the CCTA with detailed vessel-by-vessel evaluation.
Our analyses may also:
Measurable & actionable insights
Cleerly Reports include an interactive, web-based summary and details of our AI-based plaque, stenosis and ischemia analysis to help providers translate clinical data for personalized CAD diagnosis and treatment.
Provider reports include an interactive, web-based summary of findings and details on the total amount and type of plaque, severity of stenoses, and likelihood of ischemia within individual vessels.
Efficient workflows
CCTA uploads for Cleerly analysis can be done a number of ways, including through direct upload, the Nuance Powershare network, intelerad Inteleshare, and Cleerly Proxy. Cleerly Proxy is a cloud-based solution with minimal onsite footprint that integrates into existing hospital, health system, and practice workflows.
Cleerly reports are typically available within two hours, and can be received via email, DICOM PDF, DICOM SC or our web portal.
Non-invasive Heart Disease Technology
Curious how Cleerly’s non-invasive heart disease technology stacks up against current standards of care? Watch Stress Less: How AI-Enabled CCTA Outperforms Stress Testing for Heart Disease Evaluation, which is part of our Transforming Cardiac Care webinar series.
"Cleerly has revolutionized our clinical ability to accurately diagnose and quantify coronary artery disease."
-
References
1 Data on File
2 Data on File
3 Data on File
4 Omori, Hiroyuki, et al. Determination of lipid-rich plaques by artificial intelligence-enabled quantitative computed tomography using near-infrared spectroscopy as reference. Atherosclerosis, vol. 386, 2023
5 Omori, Hiroyuki, et al. Determination of lipid-rich plaques by artificial intelligence-enabled quantitative computed tomography using near-infrared spectroscopy as reference. Atherosclerosis, vol. 386, 2023
6 Nurmohamed, N, Danad, I, Jukema, R. et al. Development and Validation of a Quantitative Coronary CT Angiography Model for Diagnosis of Vessel-Specific Coronary Ischemia. J Am Coll Cardiol Img. 2024 Aug, 17 (8) 894–906
7 Choi AD, et al. CT Evaluation by Artificial Intelligence for Atherosclerosis, Stenosis and Vascular Morphology (CLARIFY): A Multi-center, international study. J Cardiovasc Comput Tomogr. 2021 Nov-Dec;15(6):470-476. Doi: 10.1016/j.jcct.2021.05.004. Epub 2021 Jun 12.
8 Griffin, William F et al. AI Evaluation of Stenosis on Coronary CTA, Comparison With Quantitative Coronary Angiography and Fractional Flow Reserve: A CREDENCE Trial Substudy. JACC. Cardiovascular imaging vol. 16,2 (2023): 193-205. doi:10.1016/j.jcmg.2021.10.020
9 Chang, Hyuk-Jae et al. Coronary Atherosclerotic Precursors of Acute Coronary Syndromes. Journal of the American College of Cardiology vol. 71,22 (2018): 2511-2522. doi:10.1016/j.jacc.2018.02.079
10 Nurmohamed, Nick S et al. Atherosclerosis quantification and cardiovascular risk: the ISCHEMIA trial. European heart journal, 5 Aug. 2024, doi:10.1093/eurheartj/ehae471
11 Kim Y, Choi AD, Telluri A, et al. Atherosclerosis Imaging Quantitative Computed Tomography (AI-QCT) to guide referral to invasive coronary angiography in the randomized controlled CONSERVE trial. Clin Cardiol. 2023 May;46(5):477-483. doi:10.1002/clc.23995. Epub 2023 Feb 27
Ready to meet the challenge?
Learn how Cleerly’s AI-enabled CCTA analysis can help prevent heart attacks and improve disease treatment.